Tumor progression relies on the ability of cancer cells to effectively invade surrounding
tissues and propagate. Among the many mechanisms that contribute to tumor progression is …

Esophageal cancer (EC) is one of the most common cancers with high morbidity and
mortality rates. EC includes two histological subtypes, namely esophageal squamous cell …

Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies (Abs) and anti-cytotoxic
T lymphocyte antigen 4 (CTLA-4) Abs, are effective for patients with various cancers …

Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a
new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic …

The advent of immune checkpoint inhibitors (ICIs) has led to noteworthy progressions in the
management of diverse cancer types, as evidenced by the pioneering “ipilimumab” …

Immune checkpoint inhibitors (ICIs) have opened up a new way for tumor therapy but
simultaneously led to the occurrence of immune-related adverse events. We report a case of …

The use of the humanized monoclonal anti–programmed cell death 1 antibodies
pembrolizumab and nivolumab as potent anticancer therapies is rapidly increasing …

Nivolumab is a fully human immunoglobulin G4 used for the treatment of several advanced
solid cancers as immune checkpoint inhibitors. There are some challenges for the …

Simple Summary In ovarian cancer, about 70% of patients experience relapse despite
primary cytoreductive surgery and platinum-based chemotherapy. The occurrence of …

Precision treatment of cancer requires knowledge on active tumor driving signal
transduction pathways to select the optimal effective targeted treatment. Currently only a …